EN DE
Watch Mangalam Drugs And Organics Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mangalam Drugs And Organics Limited (MANGALAM) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Mangalam Drugs And Organics Limited stock ₹29.66, price ₹28.60, upside +3.7%, quality 29 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE584F01014

MD Mangalam Drugs And Organics Limited logo Thin data Nov 16, 2026

Mangalam Drugs And Organics Limited

MANGALAM · NSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value ₹29.66 · Fairly valued 
Mixed Growth (revenue YoY −26.9 %/yr in INR) 
Mixed vs. peers (5/11) 
Changed on Oct 30: ₹24.94 → ₹29.66 
Quality 29/100 
Falling price (downtrend) 
Loss-making · -16.5% net margin (TTM) 
Negative free cash flow 
Narrow moat 9/100
Thin data 
Watch Mangalam Drugs And Organics Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹189.50 ₹23.78 Fair Value ₹29.66 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₹23.78 – ₹189.50 · fair‑value band ₹22.14 – ₹44.27 · the ₹28.60 price screens below the ₹29.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow Mangalam Drugs And Organics in your weekly email

Every Wednesday you see whether Mangalam Drugs And Organics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.

Show moreShow less

The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate.

It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base.

In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals.

Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications.

Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.

Stock analysis

Mangalam Drugs And Organics Limited (MANGALAM) currently trades at ₹28.60, while our model-based Fair Value estimate is ₹29.66, so the stock looks roughly fairly valued today (gap 3.6%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: ₹22.14 (bear) to ₹44.27 (bull), the price of ₹28.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

Mangalam Drugs And Organics Limited reported revenue of ₹2.3B in FY2026 versus ₹4.5B in FY2022, a compound −15.1%/yr. Reported net income was −₹444M in FY2026.

Key figures

Market cap ₹453M (≈ $4.8M) Micro · P/S ratio 0.20 · EPS (TTM) ₹−24.16 · Dividend yield 9.0% · Net margin −16.5% · Return on equity −35.2% · Return on assets (EBIT) 1.9% (5-year average) · Operating margin −5.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 53% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 4%, MANGALAM screens cheaper than that median.

Fair Value models

Bear ₹22.14 Fair Value ₹29.66 Bull ₹44.27
Price ₹28.60 · Upside +3.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) ₹22.14 ₹29.66 ₹44.27 54
All 1 models by family
Asset-Based
NCAV (Graham) ₹22.14 ₹29.66 ₹44.27 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 23
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 28
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.7% (2021) → −14.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch MANGALAM, get fair value alerts →

Compare Mangalam Drugs And Organics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside +1.5% · Above median
Profitability
Return on assets −14.1% · Bottom 25%
Net margin (12 months) −16.5% · Bottom 25%
Operating margin (12 months) −5.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.2% · Below median
Dividend yield (12 months) 9.0% · Top 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.45× · Cheapest 25%
P/S (12 months) 0.20× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)35 · sector 17
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)100 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs MANGALAM
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs MANGALAM
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs MANGALAM
Haleon plc HLN $9.17 $8.47 −8% vs MANGALAM
Merck KGaA MRK €149.60 €108.83 −27% vs MANGALAM
Galderma Group GALD CHF 191.40 CHF 112.30 −41% vs MANGALAM
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs MANGALAM
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs MANGALAM
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs MANGALAM
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs MANGALAM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mangalam Drugs And Organics Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mangalam Drugs And Organics Limited Fair Value". https://www.fairvalue-calculator.com/stock/MANGALAM

Frequently asked questions

Is Mangalam Drugs And Organics Limited (MANGALAM) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of ₹29.66 versus a price of ₹28.60, about +4% upside (fairly valued).
What is the fair value of MANGALAM?
Our model-based fair value for Mangalam Drugs And Organics Limited is ₹29.66 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹28.60.
What is the quality score of MANGALAM?
Mangalam Drugs And Organics Limited has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mangalam Drugs And Organics Limited (MANGALAM)?
Our model-based price target is the fair value of ₹29.66 (as of Nov 16, 2026) from 1 valuation models. Cautious scenario ₹22.14, optimistic scenario ₹44.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Mangalam Drugs And Organics Limited stock forecast for 2026?
Our models put fair value at ₹29.66, about +4% upside versus a price of ₹28.60 (fairly valued). Cautious scenario ₹22.14, optimistic scenario ₹44.27. The calculation is refreshed regularly with new filings.
What is the revenue of Mangalam Drugs And Organics Limited (MANGALAM)?
Mangalam Drugs And Organics Limited reported trailing-twelve-month revenue of about ₹2.3B (latest available figure, as of Nov 16, 2026).
Does Mangalam Drugs And Organics Limited pay a dividend?
Mangalam Drugs And Organics Limited currently shows a dividend yield of 8.95% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Mangalam Drugs And Organics Limited (MANGALAM)?
Mangalam Drugs And Organics Limited has a dividend yield of 9.0%.
What is the intrinsic value of Mangalam Drugs And Organics Limited (MANGALAM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mangalam Drugs And Organics Limited it is ₹29.66 per share (as of Nov 16, 2026), against a price of ₹28.60. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Mangalam Drugs And Organics Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, MANGALAM trades below its calculated fair value: price ₹28.60, fair value ₹29.66, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MANGALAM?
No. The price is what the market pays today (₹28.60); the fair value is what the company's own numbers justify (₹29.66). For Mangalam Drugs And Organics Limited the two are ₹1.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mangalam Drugs And Organics Limited worth?
The market values Mangalam Drugs And Organics Limited at about ₹453M (market capitalisation, as of Nov 16, 2026). Per share that is ₹28.60; our models calculate a fair value of ₹29.66 per share.
What do the bullish and bearish scenarios say about MANGALAM?
Our models span a range for Mangalam Drugs And Organics Limited: cautious scenario ₹22.14, base ₹29.66, optimistic ₹44.27 per share (as of Nov 16, 2026, price ₹28.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mangalam Drugs And Organics Limited (MANGALAM)?
Balance-sheet figures for Mangalam Drugs And Organics Limited (as of Nov 16, 2026): return on equity −35.2%, debt of 0.07 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is MANGALAM from its 52-week high?
Mangalam Drugs And Organics Limited trades at ₹28.60, about 53% below its 52-week high of ₹61.20 and 20% above the low of ₹23.78 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹29.66 is for.
Which stocks are comparable to Mangalam Drugs And Organics Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mangalam Drugs And Organics Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹28.60, calculated fair value ₹29.66 (+4%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MANGALAM calculated?
We run Mangalam Drugs And Organics Limited through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of ₹29.66 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Mangalam Drugs And Organics Limited currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mangalam Drugs And Organics Limited (MANGALAM)?
The closing price on Nov 16, 2026 was ₹28.60. Our model-based fair value is ₹29.66, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mangalam Drugs And Organics Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹22.14 to ₹44.27) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Mangalam Drugs And Organics Limited

How large is the market capitalisation of Mangalam Drugs And Organics Limited (MANGALAM)?
The market capitalisation of Mangalam Drugs And Organics Limited is ₹453M (≈ $4.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mangalam Drugs And Organics Limited (MANGALAM)?
The price-to-sales ratio of Mangalam Drugs And Organics Limited is 0.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mangalam Drugs And Organics Limited (MANGALAM)?
Earnings per share at Mangalam Drugs And Organics Limited are ₹−24.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mangalam Drugs And Organics Limited (MANGALAM)?
The dividend yield of Mangalam Drugs And Organics Limited is 9.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mangalam Drugs And Organics Limited (MANGALAM)?
The net margin of Mangalam Drugs And Organics Limited is −16.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mangalam Drugs And Organics Limited (MANGALAM)?
The return on equity (ROE) of Mangalam Drugs And Organics Limited is −35.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mangalam Drugs And Organics Limited (MANGALAM)?
On an EBIT basis the return on assets of Mangalam Drugs And Organics Limited is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mangalam Drugs And Organics Limited (MANGALAM)?
The operating margin of Mangalam Drugs And Organics Limited is −5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mangalam Drugs And Organics Limited (MANGALAM)?
Revenue at Mangalam Drugs And Organics Limited is down 0.2% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mangalam Drugs And Organics Limited (MANGALAM)?
Earnings per share at Mangalam Drugs And Organics Limited are down 98.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mangalam Drugs And Organics Limited (MANGALAM) generate?
The free cash flow of Mangalam Drugs And Organics Limited is −₹208M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mangalam Drugs And Organics Limited (MANGALAM) carry?
The net debt of Mangalam Drugs And Organics Limited is ₹1.0B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Mangalam Drugs And Organics Limited in the live analysis

One click puts Mangalam Drugs And Organics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.